Phillip D Toth
Indiana University
9 Papers
188 Citations
Phillip D Toth is an academic researcher from Indiana University. The author has contributed to research in topics: Cholesterol & Colesevelam. The author has an hindex of 8, co-authored 8 publications.
Chat about Author
Papers
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
Harold E. Bays,Paul B Moore,Margaret Drehobl,Sidney Rosenblatt,Phillip D Toth,Carlos A. Dujovne,Robert H Knopp,Leslie Lipka,Alexandre LeBeaut,Bo Yang,L. Mellars,Cynthia Cuffie-Jackson,Enrico P. Veltri +12 more
TL;DR: Ezetimibe significantly decreased plasma LDL-C levels and increased plasma HDL-C Levels, with a tolerability profile similar to that of placebo, in these two 12-week studies.
324
The Role of Lithotripsy and Its Side Effects
TL;DR: Over-all, extra-corporeal shock wave lithotripsy is associated with significantly lower morbidity than percutaneous nephrostolithotomy but stone-free rates are lower for extracorporeal shockWave lithotRIpsy than for percutaneously neph Frostolithotomy, which is slight for kidneys containing minimal stone burden but increases in direct proportion to increasing stone burden.
161
Effectiveness of Colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia : A 24-week randomized controlled trial
William Insull,Phillip D Toth,William S. Mullican,Donald B. Hunninghake,Steven K. Burke,Joanne M. Donovan,Michael H. Davidson +6 more
- 01 Oct 2001
TL;DR: Colesevelam was efficacious, decreasing mean LDL cholesterol levels by up to 18%, and well tolerated without serious adverse events, and compliance rates were between 88% and 92% for all groups.
143
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
Michael H. Davidson,Phillip D Toth,Stuart R. Weiss,James M. McKenney,Donald B. Hunninghake,Jonathan L. Isaacsohn,Joanne M. Donovan,Steven K. Burke +7 more
TL;DR: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐design study was conducted to assess the efficacy and tolerability of combination low‐dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia.
Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects: Results of a dose-response study
Harold E. Bays,Margaret Drehobl,S. Rosenblatt,Phillip D Toth,Carlos A. Dujovne,Robert H. Knopp,Leslie Lipka,Cynthia Cuffie-Jackson +7 more
23